A method for preventing or treating metabolic syndrome by administering bezafibrate. Since bezafibrate suppresses the action of 11.beta.-hydroxysteroid dehydrogenase type 1 and also accelerates expression of adiponectin receptor, it is used as an agent for preventing or treating metabolic syndrome.